Emerging Markets Earnings Roundup: Pfizer (Part 11)
This article was originally published in PharmAsia News
Executive Summary
Pfizer emerging markets growth lagged in the first quarter, something executives said would turnaround for the rest of the year. But it was almost more interesting for what they didn’t say about how AstraZeneca would fit into the emerging markets picture – particularly because the British firm had solid first quarter results in those markets, especially China.